Drug Development Boot Camp Holds True to its Name

Drug Development Boot Camp Holds True to its Name

Drug Development Boot Camp Holds True to its NameBOCA RATON, Florida – Robert Hoppes, Director of Sales for R&D for LGM Pharma, a supplier of active pharmaceutical ingredients (APIs) in Boca Raton, Florida, recently attended the Drug Development Boot Camp offered by Speid & Associates, Inc. and Harvard University’s Office of Technology Development.

This intensive two-day course for Biotech and Pharma company executives provided an opportunity for participants to obtain a hands-on insight into the drug development process from drug discovery to regulatory approval. The program presented a unique interactive platform to engage with industry colleagues from a variety of disciplines on each step of the drug development process. The drug development boot camp also presented a good forum to discuss the changing landscape of the pharmaceutical industry. Much of the dialogue was about the shift to specialization rather than having all aspects of the development process done in-house by one company. With all of the downsizing and constricting of drug pipelines, more emphasis is being placed on outsourcing expertise and increasing collaboration.

According to Mr. Hoppes, “This was a unique opportunity to be totally immersed in the drug development process and to mix with a fascinating group of professionals that have proven themselves by bringing drugs to market.”

About LGM Pharma

LGM Pharma is a leading supplier of active pharmaceutical ingredients (APIs) to various global pharmaceutical firms involved in the research and development of old and new therapeutic chemical entities. In its commitment to improving health opportunities all over the world, the company has forged partnerships with some of the biggest names in the pharmaceutical industry. Currently, the company supplies over 2,500 active pharmaceutical ingredients to its global clients. For more information, visit www.lgmpharma.com.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service